通讯作者: 王新兴, wxxemail@sina.cn

DOI：10.12201/bmr.202601.00026

Advances and Therapeutic Strategies in Targeted Delivery of Traditional Chinese Medicine for Drug-Induced Liver Injury

• 摘要：药物性肝损伤（Drug-Induced Liver Injury, DILI）是导致急性肝衰竭的主要病因之一。目前临床以停药及支持疗法为主，缺乏高效广谱的解毒手段。中医药在DILI防治中具有多靶点、整体调控的独特潜力，但其成分体系复杂、部分成分存在潜在肝毒性、口服生物利用度低以及质量控制难度大等问题，严重制约了其临床转化与应用。本文聚焦于靶向递送技术的最新进展，综述了以下策略：通过纳米载体的功能化修饰增强肝脏选择性蓄积；设计微环境响应型释药系统实现病灶区域精准控释；利用细胞外囊泡（Extracellular Vesicles, EVs）的天然靶向性与低免疫原性构建仿生递送平台。这些策略为提升中药在DILI治疗中的效率与安全性提供了关键的技术路径与转化前景。

  关键词： 药物性肝损伤; 中药; 靶向递送技术

   

  Abstract: Drug-induced liver injury (DILI) is a leading cause of acute liver failure. Current Western medical treatment primarily relies on drug discontinuation and supportive therapy, lacking efficient broad-spectrum detoxification agents, while the efficacy of N-acetylcysteine is significantly time-limited. Traditional Chinese medicine (TCM) demonstrates therapeutic potential through multi-target regulation, but its clinical translation is severely constrained by the complexity of its components and the risk of hepatotoxicity. In response to these challenges, this article systematically reviews recent advances in targeted delivery technologies: engineered modifications of nanocarriers enhance selective drug accumulation in the liver; the design of microenvironment-responsive drug release systems enables precise controlled release at the lesion site; and the use of extracellular vesicles (EVs) leverages their innate targeting capability and low immunogenicity to reduce systemic exposure risks. These strategies provide crucial technical support and a translational pathway for the effective and safe application of TCM in the treatment of DILI.

  Key words: Drug-induced liver injury; Traditional Chinese medicine; Targeted delivery technology

  提交时间：2026-01-09

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 荆茂琪, 朱磊. 伴有免疫特征药物性肝损伤的研究进展. 2025. doi: 10.12201/bmr.202504.00001

  张安安, 张锦梅, 胡丹丹. Paxlovid致迟发性药物性肝损1例并文献分析. 2025. doi: 10.12201/bmr.202502.00033

  范玲, 朱晓静. 我院281例药物性肝损伤不良反应分析. 2024. doi: 10.12201/bmr.202412.00015

  刘芷溢, 谢萍. 基于“邪伏膜原”探讨放射性阴道损伤的中医辨治. 2025. doi: 10.12201/bmr.202511.00016

  叶凤琴, 王明刚, 罗娟, 莫征远, 陈鑫鑫, 王秀峰. 免疫细胞与中医药在慢加急性肝衰竭中的作用. 2025. doi: 10.12201/bmr.202504.00030

  刘永珍, 王玲, 刘福蓉. 中医药治疗放射性口腔黏膜炎的用药规律分析. 2025. doi: 10.12201/bmr.202504.00049

  李乾艳, 方杰, 张艾丽. 银屑病临床治疗研究进展:从传统药物到生物制剂与新兴策略. 2025. doi: 10.12201/bmr.202512.00051

  陈新潮, 李灵冰, 陈曦. 中药单体在胃癌前病变中的研究进展. 2025. doi: 10.12201/bmr.202511.00037

  吕淑贞. 基于医院微信公众平台的中药配送服务患者使用意愿影响因素研究. 2022. doi: 10.12201/bmr.202209.00010

  郭晴晴. 胃肠恶性肿瘤化疗后骨髓抑制中西医研究进展. 2025. doi: 10.12201/bmr.202506.00008

• 序号	提交日期	编号	操作
  1	2025-11-04	10.12201/bmr.202601.00026V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论